Novavax to supply Switzerland with 6M doses of COVID-19 vaccine

By The Science Advisory Board staff writers

February 4, 2021 -- Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.

The vaccine is currently in phase III clinical development, and is the first to show efficacy against the original COVID-19 strain and the two variants emerging from the U.K. and South Africa, according to the firm.

The company will begin shipping the vaccine to Switzerland after the drug has undergone regulatory review, Novavax said.

Novavax to produce Canadian supply of COVID-19 vaccine in Canada
Novavax has signed a memorandum of understanding with the Canadian government to produce the company's protein-based COVID-19 vaccine candidate, NVX-CoV2373,...
Novavax COVID-19 vaccine phase III trial indicates up to 89% efficacy
Novavax announced that its protein-based COVID-19 vaccine candidate, NVX-CoV2373, met the primary end point in a U.K. phase III clinical trial, achieving...
Canada ups COVID-19 vaccine order from Novavax to 76M doses
Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19...
Novavax provides updates on COVID-19 vaccine
Novavax has reported that it is making "meaningful progress" on its COVID-19 vaccine, NVX‑CoV2373.
Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter